Vertex Pharmaceuticals News

Form 144 | Vertex Pharmaceuticals(VRTX.US) Officer Proposes to Sell 6.8 Million in Common Stocks

SEC FILLINGS DISCLOSED/ May 20, $Vertex Pharmaceuticals(VRTX.US)$ Officer Kewalramani Reshma intends to sell 15,202 shares of its common stock on May 20, with a total market value of approximately $6.

Futu News03:36

Vertex Pharmaceuticals on Track for Record High Close -- Data Talk

Vertex Pharmaceuticals Incorporated (VRTX) is currently at $447.15, up $1.94 or 0.44% --Would be new all-time high (Based on available data back to July 24, 1991) --Would be first new all-time recor

Dow Jones01:15

PTC Therapeutics Rallies 18% on EU Authorization Update for Translarna

Seeking AlphaMay 20 21:58

Vertex Pharmaceuticals Hits 15-week High

Trading EconomicsMay 20 21:56

Vertex Pharmaceuticals(VRTX.US) Officer Sells US$13,789.76 in Common Stock

$Vertex Pharmaceuticals(VRTX.US)$ Officer Sachdev Amit sold 32 shares of common stock on May 15, 2024 at an average price of $430.93 for a total value of $13,789.76.Source: Announcement What is statem

Futu NewsMay 18 05:14

Vertex Pharmaceuticals(VRTX.US) Officer Sells US$29,734.17 in Common Stock

$Vertex Pharmaceuticals(VRTX.US)$ Officer Arbuckle Stuart A sold 69 shares of common stock on May 15, 2024 at an average price of $430.93 for a total value of $29,734.17.Source: Announcement What is s

Futu NewsMay 18 05:08

Vertex Pharmaceuticals(VRTX.US) Officer Sells US$23,270.22 in Common Stock

$Vertex Pharmaceuticals(VRTX.US)$ Officer ALTSHULER DAVID sold 54 shares of common stock on May 15, 2024 at an average price of $430.93 for a total value of $23,270.22.Source: Announcement What is sta

Futu NewsMay 18 05:06

Vertex Pharmaceuticals's Options Frenzy: What You Need to Know

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals.

BenzingaMay 16 04:31

Jennifer Schneider Elected to Vertex Board of Directors

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Jennifer Schneider, M.D., M.S., has been elected to its Board of Directors as an independent director. Dr. Schneider has more than two decades of

BusinesswireMay 15 22:30

Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'

On CNBC's "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said under $30, Pfizer Inc. (NYSE:PFE) is a gift.Pfizer is looking to build on the success of its COVID-19 vaccine

BenzingaMay 15 21:07

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 9.86% on an annualized basis producing an average annual return of 20.63%.

BenzingaMay 14 22:00

Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497

Vertex Pharmaceuticals (VRTX) has an average outperform rating and a price target range of $325 to $577, according to analysts polled by Capital IQ. Price: 430.50, Change: +0.57, Percent Change: +0.13

MT NewswiresMay 14 17:43

Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart Buy

The Motley FoolMay 13 02:47

8 Out of 12 S&P 500 Healthcare Companies Beat Profit Consensus This Week: Earnings Scorecard

Seeking AlphaMay 12 23:22

Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone

Alpine Immune Sciences (ALPN) and Vertex Pharmaceuticals (VRTX) said Friday the waiting period under the Hart-Scott-Rodino antitrust act related to their merger deal expired Thursday. Vertex has agree

MT NewswiresMay 11 03:32

HHS Panel to Vote in Nov. on DMD Screening for Newborns

Seeking AlphaMay 10 06:44

Press Release: Alpine Immune Sciences Reports First Quarter 2024 Financial Results

Alpine Immune Sciences Reports First Quarter 2024 Financial Results SEATTLE--(BUSINESS WIRE)--May 09, 2024-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy compa

Dow JonesMay 10 04:00

Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Will Probably Have Their Compensation Approved By Shareholders

We have been pretty impressed with the performance at Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) recently and CEO Reshma Kewalramani deserves a mention for their role in it.

Simply Wall StMay 9 20:48

Decoding Vertex Pharmaceuticals Inc (VRTX): A Strategic SWOT Insight

Vertex Pharmaceuticals Inc (NASDAQ:VRTX), a leading global biotechnology firm, recently released its 10-Q filing on May 7, 2024, offering a detailed glimpse into its financial and operational performance.

Yahoo FinanceMay 9 13:04

Stifel Nicolaus Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

In a report released yesterday, Paul Matteis from Stifel Nicolaus maintained a Hold rating on Vertex Pharmaceuticals (VRTX), with a price target of $420.00.

TipRanksMay 9 10:07